Crossmark Global Holdings’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.6M | Sell |
2,957
-107
| -3% | -$60.3K | 0.02% | 518 |
|
|
2026
Q1 | $1.82M | Sell |
3,064
-217
| -7% | -$108K | 0.03% | 456 |
|
|
2025
Q4 | $1.6M | Sell |
3,281
-218
| -6% | -$102K | 0.02% | 485 |
|
|
2025
Q3 | $1.47M | Buy |
3,499
+14
| +0.4% | +$4.71K | 0.02% | 527 |
|
|
2025
Q2 | $1M | Sell |
3,485
-160
| -4% | -$47.8K | 0.02% | 607 |
|
|
2025
Q1 | $1.12M | Buy |
3,645
+123
| +3% | +$42.2K | 0.02% | 574 |
|
|
2024
Q4 | $1.24M | Sell |
3,522
-62
| -2% | -$22.8K | 0.02% | 519 |
|
|
2024
Q3 | $1.28M | Buy |
3,584
+608
| +20% | +$205K | 0.02% | 528 |
|
|
2024
Q2 | $948K | Sell |
2,976
-653
| -18% | -$173K | 0.02% | 598 |
|
|
2024
Q1 | $833K | Buy |
3,629
+62
| +2% | +$14K | 0.02% | 673 |
|
|
2023
Q4 | $784K | Sell |
3,567
-455
| -11% | -$105K | 0.02% | 674 |
|
|
2023
Q3 | $926K | Sell |
4,022
-104
| -3% | -$24K | 0.02% | 594 |
|
|
2023
Q2 | $1.01M | Sell |
4,126
-264
| -6% | -$58.5K | 0.02% | 585 |
|
|
2023
Q1 | $983K | Buy |
4,390
+134
| +3% | +$33K | 0.02% | 588 |
|
|
2022
Q4 | $1.18M | Buy |
4,256
+26
| +0.6% | +$6.56K | 0.03% | 524 |
|
|
2022
Q3 | $886K | Sell |
4,230
-38
| -0.9% | -$8.49K | 0.02% | 577 |
|
|
2022
Q2 | $1.01M | Sell |
4,268
-880
| -17% | -$179K | 0.03% | 563 |
|
|
2022
Q1 | $923K | Sell |
5,148
-500
| -9% | -$95.3K | 0.02% | 651 |
|
|
2021
Q4 | $1.22M | Sell |
5,648
-90
| -2% | -$17.7K | 0.03% | 566 |
|
|
2021
Q3 | $1.06M | Buy |
5,738
+1,790
| +45% | +$353K | 0.02% | 594 |
|
|
2021
Q2 | $708K | Sell |
3,948
-120
| -3% | -$22.9K | 0.02% | 742 |
|
|
2021
Q1 | $680K | Sell |
4,068
-30
| -0.7% | -$5K | 0.02% | 747 |
|
|
2020
Q4 | $622K | Sell |
4,098
-90
| -2% | -$11.8K | 0.02% | 752 |
|
|
2020
Q3 | $423K | Buy |
4,188
+130
| +3% | +$14.3K | 0.01% | 845 |
|
|
2020
Q2 | $491K | Buy |
4,058
+461
| +13% | +$51.9K | 0.01% | 764 |
|
|
2020
Q1 | $341K | Sell |
3,597
-130
| -3% | -$12.4K | 0.01% | 789 |
|
|
2019
Q4 | $328K | Buy |
3,727
+60
| +2% | +$5.28K | 0.01% | 1059 |
|
|
2019
Q3 | $292K | Sell |
3,667
-180
| -5% | -$14.5K | 0.01% | 1068 |
|
|
2019
Q2 | $300K | Sell |
3,847
-160
| -4% | -$15K | 0.01% | 1099 |
|
|
2019
Q1 | $470K | Buy |
4,007
+70
| +2% | +$8.16K | 0.01% | 846 |
|
|
2018
Q4 | $429K | Sell |
3,937
-1,180
| -23% | -$137K | 0.01% | 846 |
|
|
2018
Q3 | $654K | Sell |
5,117
-510
| -9% | -$63.1K | 0.02% | 783 |
|
|
2018
Q2 | $637K | Buy |
5,627
+160
| +3% | +$17.6K | 0.02% | 792 |
|
|
2018
Q1 | $614K | Sell |
5,467
-975
| -15% | -$124K | 0.02% | 805 |
|
|
2017
Q4 | $953K | Buy |
6,442
+75
| +1% | +$9.53K | 0.02% | 660 |
|
|
2017
Q3 | $746K | Buy |
+6,367
| New | +$813K | 0.02% | 741 |
|
|
2016
Q3 | $746K | Buy |
+6,367
| New | +$765K | 0.02% | 741 |
|
Other funds holding UTHR
ACA
JT
Crossmark Global Holdings's UTHR Position: Q2 2026 in Review
Crossmark Global Holdings reduced its United Therapeutics (UTHR) stake by 3.5% in Q2 2026, selling an estimated $60.3K and leaving 2,957 shares worth $1.6M. The position accounts for 0.02% of the portfolio, ranked #518.
Crossmark Global Holdings first reported a position in UTHR in Q3 2016 and has held it in 37 quarters since. The position peaked at $1.82M in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Crossmark Global Holdings held 2,957 shares of United Therapeutics worth $1.6M as of Q2 2026.
- Crossmark Global Holdings sold 107 United Therapeutics shares in Q2 2026, an estimated $60.3K.
- United Therapeutics made up 0.02% of Crossmark Global Holdings's portfolio in Q2 2026, its #518 holding.
- Crossmark Global Holdings first reported a position in United Therapeutics in Q3 2016 and has held it in 37 quarters since.
- Crossmark Global Holdings's United Therapeutics position peaked at $1.82M in Q1 2026.
- 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.